UNSPSC 51262205: Proroxan hydrochloride

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C21H23NO3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 694Z9P44G4, chemically known as 1,4-benzodioxan, 6-(3-(3-phenylpyrrolidinyl)propionyl)-, hydrochloride but more generally known as proroxan hydrochloride, which bears US NIH Compound Identifier 36302. Most nations, for tariff and trade purposes, schedule proroxan hydrochloride under HS 29349990 and SITC 51579.

As of Q4 2014, PROROXAN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Proroxan hydrochloride bears US NLM identifiers UMLS ID C0951999 and NCI Concept Code C84120. SMILES: C1CCC(CC1)C2CCN(C2)CCC(=O)C3CCC4C(C3)OCCO4.CL.

UNSPSC 51262205 Proroxan hydrochloride is a Commodity code designating a specific pharmaceutical product; however, the single recent state and local opportunity tagged to this code does not match its nominal scope. Seminole County, Florida's IFB60459723LAS solicitation, posted June 30, 2026, seeks Naloxone and Safe Drug Deactivation Systems — distinct products unrelated to proroxan hydrochloride. The county procurement does not indicate that proroxan is part of the requirement. This mismatch suggests either a UNSPSC coding error in the county's procurement system or a misalignment between the opportunity's actual scope and its taxonomic classification. The code shows little relevant recent activity under its intended product definition.

The Seminole County opportunity itself targets county-level health procurement, with an IFB response deadline of July 26, 2023 (note: the posted date of June 30, 2026, appears inconsistent with the 2023 response deadline in the source). The solicitation calls for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The contract includes an initial two-year term with a one-year renewal option, requires electronic bid submission, E-Verify compliance, standard insurance coverage, and potential FEMA funding with associated federal compliance obligations. No explicit disadvantaged-enterprise set-asides are mentioned. Absent other recent opportunities under this Commodity code, pursuit decisions should focus on clarifying whether the code's actual scope aligns with your firm's pharmaceutical capabilities or whether this represents a data-quality issue in the county's procurement classification system.